Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹7,352 Cr
verified against source
Revenue YoY
14.7%
reported change
EBITDA
₹1,601 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Aurobindo Pharma reported Q3 FY24 revenue of INR 7,352 crore (+14.7% YoY) and EBITDA margin of 21.8%, driven by strong US formulation growth (+28.9% YoY) and injectable/specialty revenue surging 58% YoY to $112M, partly from Revlimid. PAT grew 19.6% YoY to INR 936 crore. Management reiterated FY24 EBITDA margin target of 20%, supported by cost efficiencies and new product launches. However, Eugia Unit III received an FDA Form 483 with 9 observations, leading to a temporary manufacturing pause and an estimated $20M revenue impact in Q4. Biosimilar pipeline advances with trastuzumab approval in India and Phase III trials for omalizumab. Key risk: prolonged Eugia Unit III shutdown could erode market share in injectable products.
Colored figures show movement against the previous available record.
Guidance to track
- Management reiterated confidence in achieving 20% EBITDA margin for FY24, supported by operational efficiencies and cost improvements.
- Non-aseptic lines expected to restart by end of February 2024; aseptic lines within 1-2 months; full production by end of FY24.
- The China oral solids plant has received cGMP approval and is expected to start generating revenue from Q1 or Q2 of FY2025.
- Management guided Xolair biosimilar revenue potential of $120M-$180M by 2028, assuming approvals in US and Europe.
Risks flagged
- FDA issued Form 483 with 9 observations at Eugia Unit III; manufacturing paused, expected $20M revenue impact in Q4. Risk of prolonged shutdown and market share loss.
- Analyst raised concern about losing market share in key products from Eugia Unit III; management acknowledged risk but expects to recover with existing stock and phased restart.
- Analyst questioned profitability if Pen G prices fall below $20/kg; management deferred response, indicating uncertainty.
- Pneumococcal vaccine missed national tender timeline; management indicated no near-term market entry, highlighting execution risk in biosimilar launches.
Key quotes
- We are confident of achieving 20% EBITDA margin target, set internally for the year, as mentioned in the previous quarter.
- I see 2026 as an inflection point for this business. For the hard yards that have been put in and the investment prudence that we have followed...
- We have taken these aggressive measures because we believe it is the most responsible and appropriate course of action until we conduct investigation and assessment to give FDA assurance that we are addressing its observations.
Research modules